GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007180611 | Liver | HCC | protein transmembrane transport | 47/7958 | 59/18723 | 5.82e-09 | 1.51e-07 | 47 |
GO:006500211 | Liver | HCC | intracellular protein transmembrane transport | 41/7958 | 51/18723 | 3.41e-08 | 7.61e-07 | 41 |
GO:003424921 | Liver | HCC | negative regulation of cellular amide metabolic process | 144/7958 | 273/18723 | 3.80e-04 | 2.61e-03 | 144 |
GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
GO:00718068 | Oral cavity | OSCC | protein transmembrane transport | 43/7305 | 59/18723 | 1.32e-07 | 2.22e-06 | 43 |
GO:00650025 | Oral cavity | OSCC | intracellular protein transmembrane transport | 36/7305 | 51/18723 | 4.79e-06 | 5.47e-05 | 36 |
GO:00429873 | Oral cavity | OSCC | amyloid precursor protein catabolic process | 40/7305 | 68/18723 | 7.28e-04 | 3.98e-03 | 40 |
GO:00429823 | Oral cavity | OSCC | amyloid precursor protein metabolic process | 52/7305 | 95/18723 | 1.33e-03 | 6.62e-03 | 52 |
GO:00342495 | Oral cavity | OSCC | negative regulation of cellular amide metabolic process | 130/7305 | 273/18723 | 2.20e-03 | 1.00e-02 | 130 |
GO:00504353 | Oral cavity | OSCC | amyloid-beta metabolic process | 36/7305 | 67/18723 | 1.01e-02 | 3.51e-02 | 36 |
GO:00342052 | Oral cavity | OSCC | amyloid-beta formation | 31/7305 | 57/18723 | 1.32e-02 | 4.38e-02 | 31 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RTN2 | SNV | Missense_Mutation | novel | c.731G>C | p.Gly244Ala | p.G244A | O75298 | protein_coding | deleterious_low_confidence(0.02) | benign(0.341) | TCGA-85-A53L-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RTN2 | SNV | Missense_Mutation | | c.179G>T | p.Arg60Leu | p.R60L | O75298 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.995) | TCGA-CX-7219-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RTN2 | SNV | Missense_Mutation | | c.1516N>A | p.Val506Met | p.V506M | O75298 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-BR-4370-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RTN2 | SNV | Missense_Mutation | | c.162N>T | p.Gln54His | p.Q54H | O75298 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.598) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RTN2 | SNV | Missense_Mutation | | c.776N>T | p.Thr259Met | p.T259M | O75298 | protein_coding | deleterious_low_confidence(0.05) | benign(0.015) | TCGA-CG-4305-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR |
RTN2 | SNV | Missense_Mutation | | c.776C>T | p.Thr259Met | p.T259M | O75298 | protein_coding | deleterious_low_confidence(0.05) | benign(0.015) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
RTN2 | SNV | Missense_Mutation | novel | c.1138N>T | p.Ala380Ser | p.A380S | O75298 | protein_coding | tolerated(0.05) | benign(0.186) | TCGA-D7-6526-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
RTN2 | SNV | Missense_Mutation | | c.404G>A | p.Arg135His | p.R135H | O75298 | protein_coding | tolerated_low_confidence(0.29) | benign(0) | TCGA-D7-A4YV-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RTN2 | SNV | Missense_Mutation | rs774982121 | c.469G>A | p.Gly157Arg | p.G157R | O75298 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.832) | TCGA-VQ-A8E2-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | fluorouracil | CR |